Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections after a year, without affecting the rate of relapses in stable multiple sclerosis (MS). That’s according to an analysis of a U.S. healthcare claims database, which compared switchers against…
News
Relapsing-remitting multiple sclerosis (RRMS) patients with low educational attainment are more likely to delay the start of disease-modifying therapies (DMTs) after a diagnosis than those with a high educational status, a Danish study suggests. Educational status wasn’t significantly associated with diagnostic delays after the onset of symptoms,…
In a new deal, TG Therapeutics will use MaxCyte’s engineering technology to develop and manufacture its off-the-shelf CAR T-cell therapy candidate azercabtagene zapreleucel — azer-cel for short — for adults with progressive forms of multiple sclerosis (MS). The experimental treatment is being advanced toward a Phase 1…
Navigating the uncertainty of living with relapsing-remitting multiple sclerosis (RRMS) brings a number of challenges, a study shows. That uncertainty is best described as the intangible, difficult to define space between hope — the sense that things might get better or at least not turn out so badly —…
Children with multiple sclerosis (MS) who were exposed to sunlight for at least half an hour per day during the first summer of life tend to have less disease relapses than those who received less sun exposure during that period, a study found. The risk of relapse was also…
The Floodlight MS app, a digital health application used to track dexterity, walking function, and cognition in people with multiple sclerosis (MS), has been deemed cost-effective in a new analysis. Modeling simulations showed MS patients who use the app experience fewer relapses and slower disability progression, which would improve…
Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with multiple sclerosis (MS) in those countries, a step designed to help general practitioners and neurologists navigate the new MS treatment landscape. “Through these guidelines, we aim to support safe, timely and…
The rate of relapses in children with pediatric-onset multiple sclerosis (POMS) tends to increase around the time that menstruation begins, a new study reports. The findings suggest hormonal changes at the onset of puberty may trigger higher disease activity. The use of oral and infusion disease-modifying therapies (DMT)…
Smoking and obesity are both independently associated with faster disease progression in multiple sclerosis (MS), but when both risk factors are present together, a synergistic effect results in faster disease progression than can be explained by either alone. “Smoking and obesity significantly interacted to increase the risk of disability…
Nearly all adults with relapsing forms of multiple sclerosis (MS) said they are highly satisfied with the Sensoready autoinjector pen to self-administer Kesimpta (ofatumumab), according to a recent U.S. survey. High satisfaction was mainly driven by the reasonable administration time and ease of use, the researchers said. The…
A Phase 2 clinical trial is currently recruiting adults with relapsing types of multiple sclerosis (MS) to investigate Zenas Biopharma’s experimental therapy obexelimab as a weekly subcutaneous, or under-the-skin, injection, the company has announced in a press release. The study, called MoonStone (NCT06564311), is open to…
Severe obesity during childhood and adolescence more than triples the risk of developing multiple sclerosis (MS), and losing weight through early lifestyle changes did not decrease the likelihood of MS, according to a nationwide study in Sweden. Although the overall risk remained low, with 0.13% of people…
Multiple sclerosis (MS) patient Lynda Whitton has been granted MS Australia’s 2024 John Studdy Award in recognition of her advocacy, leadership, and fundraising efforts for MS and other neurological diseases in her hometown of Bunbury and across Australia. The nonprofit’s top award is given each year to people…
Mikael Simons, MD, a neurologist at Technical University Munich, has been awarded this year’s $125,000 Barancik Prize for his extensive research on myelin, a protective coating that sheathes nerve cells and becomes damaged in multiple sclerosis (MS). Run by the National MS Society and funded by the Charles…
Less frequent Ocrevus (ocrelizumab) infusions are as effective as standard dosing — when treatment is given typically every six months — for controlling multiple sclerosis (MS) disease activity, but may help limit the risk of side effects, a new study reports. “These findings suggest that [extended-interval dosing] could…
A three-month course of acupuncture was associated with gains in certain aspects of cognition for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial. The traditional Chinese medicine was also linked to less fatigue, improved sleep, and reductions in certain psychological problems such as depression. The findings…
While people with multiple sclerosis (MS) seem to get a similar quantity of sleep relative to individuals without the disease, MS patients have significantly worse sleep quality than their healthy counterparts, according to a new review of several published studies. The findings show that MS may affect a person’s…
Women with multiple sclerosis (MS) face a significantly higher risk of mental illness during and after pregnancy than those without the disease, according to a new study that analyzed data from more than 890,000 women in Canada. Mental health issues, mostly anxiety and depression, affected 42% of women…
Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are young, early in the disease course, do not have other major health issues, and have failed to respond to available medications, according to a new set of recommendations. The procedure…
Intranasal foralumab can modulate a number of immune cell types in people with nonactive secondary progressive multiple sclerosis (SPMS), a study showed, revealing new immune biomarkers that show how the therapy exerts its effects in people with the condition. After three months of treatment, gene activity data showed that…
Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize microglia activity in people with neurodegenerative diseases such as multiple sclerosis (MS). Microglia are resident immune cells in the brain that are believed to play a role in driving…
The U.S. Food and Drug Administration (FDA) has added a new boxed warning to the prescribing information for glatiramer acetate, an approved injection therapy for relapsing forms of multiple sclerosis (MS) that’s sold under the brand name Copaxone and is also available as generic products. A boxed warning…
A 14-week regimen of physical therapy combined with PoNS — a neurostimulator device used to improve mobility — led to significant gait improvements in people with multiple sclerosis (MS), with evidence that its benefits are sustained over time, according to new data from the real-world PoNSTEP clinical study.
Tech company Century Health has entered into a partnership to organize and clean Nira Medical‘s datasets from more than 3,000 people with multiple sclerosis (MS) to help make clinical data more available for researchers to explore insights toward developing new treatments. “We’re thrilled to partner with Nira…
A new website aims to provide support to caregivers of people with multiple sclerosis (MS). The site, MS Care Partner Connection, brings together information on how caregivers can care for themselves while tending to those living with the disease, how to navigate the healthcare system, and how to…
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in healthy volunteers. The therapy is a selective small molecule antagonist, or inhibitor, of the GPR17 receptor and is designed to restore…
TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi (ublituximab-xiiy), its approved therapy for relapsing forms of multiple sclerosis (MS). The company said it plans to start a pivotal clinical program this year which could support an application seeking approval of the…
Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, is able to detect regions of damage and other disease-related features while using 60% less gadolinium — a chemical element used to enhance an MRI — compared with existing gadolinium-based contrast agents. That’s according to new data…
Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS). The company sought permission last year from the U.S. Food and Drug Administration (FDA) to start the study. Once such…
For women with multiple sclerosis (MS), disability starts to worsen significantly faster after menopause, according to a new study. “The study shows that menopause represents a unique factor in MS progression, even when we take into consideration the effects of aging,” Riley Bove, MD, study co-author at the University…